Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe
SK Biopharmaceuticals and Arvelle Therapeutics GmbH today announced that they have entered into an exclusive licensing agreement for Arvelle to develop and commercialize cenobamate in Europe. Cenobamate is a novel, small molecule investigational antiepileptic drug for the potential treatment of partial-onset seizures in adult patients. Under the agreement, SK Biopharmaceuticals will receive an upfront payment of $100 million and is eligible to receive up to $430 million upon achievement of certain regulatory and commercial milestones in addition to royalties on net sales generated in Europe. SK Biopharmaceuticals will have an option to obtain a significant equity stake in Arvelle and will also retain commercial rights for all non-European territories. Cenobamate was discovered and developed by SK Biopharmaceuticals from inception through to the acceptance of a New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA).
“We are very pleased to enter into this licensing agreement with Arvelle, as it provides important validation of the global potential for cenobamate as a new treatment option for adults with partial-onset seizures,” said Dr. Jeong Woo Cho, President and CEO of SK Biopharmaceuticals. “Arvelle’s experienced leadership team and focus on CNS disorders make them the ideal partner to advance the development and commercialization of our compound in Europe.”
Arvelle Therapeutics is a newly created company that received one of the largest initial financing commitments for a European-focused biopharmaceutical company from a global syndicate of investors that include NovaQuest, LSP, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners. Mark Altmeyer has been named President and CEO of Arvelle. Altmeyer brings more than 30 years of global biopharmaceutical experience to Arvelle. As President and CEO of Otsuka America Pharmaceutical, Inc., Altmeyer oversaw the growth of Abilify® into a multi-billion-dollar product. Most recently, he served as President and Chief Commercial Officer of Axovant Sciences and previously led the neuroscience business unit at Bristol-Myers Squibb Company. Altmeyer is joined by a talented team of colleagues from Axovant with deep experience in CNS drug development and global commercialization. Arvelle intends to file a Marketing Authorization Application (MAA) for cenobamate for partial-onset seizures in adult patients based on the data generated from SK Biopharmaceuticals’ global clinical trial program.
“We launched Arvelle to bring truly innovative CNS products to patients suffering from serious neurological conditions and cenobamate is the perfect first pipeline product,” said Altmeyer. “Given the data generated in clinical trials and the FDA acceptance of the NDA, we believe cenobamate has the potential to be an important antiepileptic drug treatment option for adult patients suffering from partial-onset seizures. We appreciate the support and validation of our investors and are very enthusiastic about our potential in the European market.”
“We are very excited to invest in the talented team at Arvelle on this new venture,” said Martijn Kleijwegt, Managing Partner of LSP. “SK Biopharmaceuticals has done an excellent job on the discovery and development of cenobamate and we believe that Arvelle is the right company to gain EU approval for cenobamate and ultimately bring it to patients in Europe.”
About Cenobamate
Cenobamate (YKP3089) was discovered by SK Biopharmaceuticals and SK life science and is being investigated for the potential treatment of partial-onset seizures (also known as “focal seizures”) in adult patients. Cenobamate’s mechanism of action is not fully understood, but it is believed to work through two separate mechanisms: enhancing inhibitory currents through positive modulation of GABA-A receptors and decreasing excitatory currents by inhibiting the persistent sodium current.
Global trials for adults with partial-onset seizures are ongoing to evaluate cenobamate safety. An additional clinical trial is investigating cenobamate safety and efficacy for another form of epilepsy in adult patients.
The U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application for cenobamate for the potential treatment of partial-onset seizures in adults in February 2019.
Cenobamate is not approved by the FDA, European Medicines Agency (EMA) or any other regulatory authorities. Safety and efficacy have not been established.
About SK Biopharmaceuticals
SK Biopharmaceuticals is focused on research and development of treatments for disorders of central nervous system (CNS) and cancer. SK Biopharmaceuticals is an affiliate of SK Group, the second largest conglomerate in Korea.
Currently, SK Biopharmaceuticals is conducting basic research for the development of innovative new drugs at its research center in Pangyo, Gyeonggi Province, Korea. Further, the company is pursuing global clinical development and direct marketing through its U.S. subsidiary SK Life Science, Inc., in Fair Lawn, New Jersey, USA.
SK Biopharmaceuticals has a pipeline of eight compounds in development for the treatment of CNS disorders including epilepsy, sleep disorder and attention deficit hyperactivity disorder, among others. The first product the company is planning to commercialize, cenobamate (YKP3089), is an investigational compound for the potential treatment of partial-onset seizures in adult patients. The NDA for cenobamate for the potential treatment of partial-onset seizures in adult patients is currently under review by the FDA. For more information, visit SK Biopharmaceuticals’ website at www.skbp.com/eng.
About Arvelle Therapeutics
Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle is responsible for the development and commercialization of cenobamate, an investigational antiepileptic drug, in the European market. Arvelle is headquartered in Switzerland and received one of the largest initial financing commitments for a European-focused biopharmaceutical company with investments from a global syndicate including NovaQuest Capital Management, LSP, BRV Capital Management, Andera Partners and H.I.G. BioHealth Partners. More information is available at http://arvelletx.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190214005290/en/
Contact information
For Arvelle Therapeutics:
Mike Beyer, Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Experian Named a Leader in IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment7.11.2025 16:00:00 EET | Press release
Experian today announced it has been named a leader in the IDC MarketScape: Worldwide Identity Verification in Financial Services 2025 Vendor Assessment (doc # US52985325, September 2025). The report evaluates vendors on the depth and breadth of their identity verification capabilities and on how effectively they align with current and future customer needs. The IDC MarketScape methodology for this assessment involved two key measures of success: capabilities that reflect Experian’s current menu of services and how well aligned they are to its customer needs as well as strategies that indicate how well Experian’s future strategy aligns with what customers will require in three to five years. “This assessment offers a 360-degree view of our identity-verification solutions, and we’re very proud to be recognized as a leader,” said Keith Little, President of Experian Software Solutions at Experian. “Experian continues to listen to our clients and focus heavily on product development across
Rachelle Alexis Lim is appointed CEO of MultiSafepay as the Company Aims to Better Serve European SMEs with Innovative Solutions7.11.2025 15:12:00 EET | Press release
MultiSafepay, a leading European payment service provider, today announces that Rachelle Alexis Lim has been appointed as the new Chief Executive Officer (CEO) of MultiSafepay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107657130/en/ Rachelle Alexis Lim is appointed CEO of MultiSafepay. In her new role, Lim oversees the overall business strategy and operations of MultiSafepay, leading the company to serve a fast-growing client base of SMEs (small and medium-sized enterprises) in Europe, leveraging innovative solutions to drive their inclusive growth. She now also sits on its board of directors, following approval from the Dutch central bank, De Nederlandsche Bank (DNB). Founder Olaf Geurs, who has served as CEO since establishing MultiSafepay in 1999, will remain Chief Technology Officer (CTO). Geurs will continue to serve on the board of directors, where he and the other existing members will be joined by Lim. In his
Organon Announces Agreement to Divest its JADA ® System for Up to $465 Million to Laborie7.11.2025 14:30:00 EET | Press release
Organon (NYSE: OGN), (“Organon” or “the Company”) a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement with Laborie Medical Technologies Corp. (“Laborie”), a leading diagnostic and therapeutic medical technology company, for them to acquire the JADA System. The transaction, valued at up to $465 million, is comprised of $440 million to be paid at closing, subject to certain closing adjustments, and a potential payment of up to $25 million subject to the achievement of certain 2026 revenue targets. Approximately 100 employees are expected to transfer to Laborie as part of the agreement. “I am incredibly proud of the work the JADA team and Organon have done to help more than 136,000 new mothers in over 20 countries, positioning JADA as a recognized standard of care in postpartum hemorrhage (PPH) management,” said Organon Interim Chief Executive Officer (“CEO”) Joseph Morriss
ADNOC Partners With Comera Financial Holdings to Empower Its UAE Suppliers and SMEs With Smart Financing Solutions7.11.2025 14:23:00 EET | Press release
ADNOC has signed a strategic partnership with Comera Financial Holdings to enhance financial access for ADNOC’s UAE-based small and medium enterprises (SMEs) and suppliers. The collaboration will launch a financing program, enabling SMEs and suppliers to access working capital more efficiently to enable them to more swiftly deliver on ADNOC purchase orders (PO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107458886/en/ ADNOC Partners with Comera Financial Holdings to Empower its UAE Suppliers and SMEs with Smart Financing Solutions (Photo: AETOSWire) The initiative will boost access to liquidity while enabling scalable operations and sustainable growth for the suppliers and SMEs. The partnership reinforces ADNOC’s commitment to supporting local businesses and advancing the UAE’s economic diversification by providing practical solutions that empower SMEs to thrive and compete globally. Khaled Al Zaabi, ADNOC Group Chief
Venture Global Announces New Long-Term LNG Sales and Purchase Agreement With Greece7.11.2025 12:47:00 EET | Press release
Today, Venture Global, Inc. (NYSE: VG) and ATLANTIC – SEE LNG TRADE S.A. of Greece announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of a minimum of 0.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. Under the SPA, Atlantic-See has the potential to expand its purchase commitment. Atlantic-See LNG is a newly formed joint venture announced this week at the 6th Partnership for Transatlantic Energy Cooperation (PTEC) conference hosted in Athens, Greece between Greek companies AKTOR and DEPA. This deal marks Greece’s first ever long-term LNG supply agreement with a U.S. exporter, launching a dynamic and growing partnership between Atlantic-See LNG and Venture Global. The announcement of this supply agreement follows Venture Global’s previously announced investment in regasification capacity at the Alexandroupolis LNG import terminal in Greece, which currently accounts for approxima
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom